Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience

被引:57
|
作者
Kourelis, Taxiarchis V. [1 ]
Buadi, Francis K. [1 ]
Kumar, Shaji K. [1 ]
Gertz, Morie A. [1 ]
Lacy, Martha Q. [1 ]
Dingli, David [1 ]
Go, Ronald S. [1 ]
Kapoor, Prashant [1 ]
Lust, John A. [1 ]
Hayman, Suzanne R. [1 ]
Hwa, Yi [1 ]
Rajkumar, S. Vincent [1 ]
Zeldenrust, Steven R. [1 ]
Russell, Stephen J. [1 ]
Lin, Yi [1 ]
Leung, Nelson [1 ]
Kyle, Robert A. [1 ]
Gonsalves, Wilson I. [1 ]
Dispenzieri, Angela [1 ]
机构
[1] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA
关键词
STEM-CELL TRANSPLANTATION; ENDOTHELIAL GROWTH-FACTOR; LENALIDOMIDE; EFFICACY;
D O I
10.1002/ajh.24356
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past decade, a number of changes have occurred in the diagnostic evaluation, management, and long-term follow-up of patients with POEMS syndrome at our institution. This study included 291 patients with POEMS syndrome diagnosed at the Mayo Clinic between 1974 and 2014. Patients diagnosed after 2003 had more features of the syndrome identified at diagnosis and were more likely to receive an autologous transplant (49% versus 8%, P < 0.0001) and to have achieved a hematologic complete response (CR) to treatment (41% vs 25%, P < 0.0001). With 2273 person-years of follow-up, 10-year overall survival (OS) was 62% (95% C.I., 56%, 67%). On multivariate analysis, the three factors associated with superior OS were younger age (RR 0.98 [0.96-1.00]), albumin greater-than 3.2 g/dL (RR 0.5 [0.32-0.89]) and attainment of complete hematologic response (RR 0.4 [0.2, 0.9]). This study confirms the very good long-term outcomes of patients with POEMS syndrome and identifies two new prognostic risk factors: albumin at diagnosis and attainment of complete hematologic response. (C) 2016 Wiley Periodicals, Inc.
引用
收藏
页码:585 / 589
页数:5
相关论文
共 50 条
  • [1] The long-term outcome of Sezary syndrome: The Mayo Clinic experience
    Kubica, Agnieszka W.
    Weaver, Amy L.
    Davis, Mark D. P.
    Pittelkow, Mark R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB140 - AB140
  • [2] Hepatopulmonary syndrome: Long-term survival in the Mayo Clinic experience
    Iyer, Vivek
    Swanson, Karen
    Cartin-ceba, Rodrigo
    Krowka, Michael
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [3] Endocrinopathy in POEMS syndrome: The Mayo Clinic experience
    Gandhi, Gunjan Y.
    Basu, Rita
    Dispenzieri, Angela
    Basu, Ananda
    Montori, Victor M.
    Brennan, Michael D.
    MAYO CLINIC PROCEEDINGS, 2007, 82 (07) : 836 - 842
  • [4] POEMS syndrome: definitions and long-term outcome
    Dispenzieri, A
    Kyle, RA
    Lacy, MQ
    Rajkumar, SV
    Therneau, TM
    Larson, DR
    Greipp, PR
    Witzig, TE
    Basu, R
    Suarez, GA
    Fonseca, R
    Lust, JA
    Gertz, MA
    BLOOD, 2003, 101 (07) : 2496 - 2506
  • [5] Clinical characteristics and long-term outcome of patients with POEMS syndrome in China
    Jian Li
    Dao-Bin Zhou
    Zhen Huang
    Li Jiao
    Ming-Hui Duan
    Wei Zhang
    Yong-Qiang Zhao
    Ti Shen
    Annals of Hematology, 2011, 90 : 819 - 826
  • [6] Clinical characteristics and long-term outcome of patients with POEMS syndrome in China
    Li, Jian
    Zhou, Dao-Bin
    Huang, Zhen
    Jiao, Li
    Duan, Ming-Hui
    Zhang, Wei
    Zhao, Yong-Qiang
    Shen, Ti
    ANNALS OF HEMATOLOGY, 2011, 90 (07) : 819 - 826
  • [7] Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
    I. Vaxman
    S. K. Kumar
    F. Buadi
    M. Q. Lacy
    D. Dingli
    S. Hayman
    T. Kourelis
    R. Warsame
    Y. Hwa
    A. Fonder
    M. Hobbs
    E. Muchtar
    N. Leung
    P. Kapoor
    R. Go
    Y. Lin
    W. Gonsalves
    M. Siddiqui
    R. A. Kyle
    S. V. Rajkumar
    M. A. Gertz
    A. Dispenzieri
    Blood Cancer Journal, 13
  • [8] Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
    Vaxman, I.
    Kumar, S. K.
    Buadi, F.
    Lacy, M. Q.
    Dingli, D.
    Hayman, S.
    Kourelis, T.
    Warsame, R.
    Hwa, Y.
    Fonder, A.
    Hobbs, M.
    Muchtar, E.
    Leung, N.
    Kapoor, P.
    Go, R.
    Lin, Y.
    Gonsalves, W.
    Siddiqui, M.
    Kyle, R. A.
    Rajkumar, S. V.
    Gertz, M. A.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [9] Daratumumab, carfilzomib, pomalidomide and elotuzumab for the treatment of poems syndrome: the Mayo Clinic experience
    Vaxman, Iuliana
    Kumar, Shaji
    Buadi, Francis
    Lacy, Martha
    Dingli, David
    Fonder, Amie
    Hobbs, Miriam
    Hayman, Suzanne
    Kourelis, Taxiarchis
    Warsame, Rahma
    Muchtar, Eli
    Leung, Nelson
    Kapoor, Prashant
    Gonsalves, Wilson
    Siddiqui, Mustaqeem
    Kyle, Robert
    Rajkumar, Vincent
    Gertz, Morie
    Dispenzieri, Angela
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S125 - S125
  • [10] Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Wiseman, Gregory
    Peterson, Jennifer
    Witzig, Thomas E.
    Tun, Han W.
    BLOOD, 2019, 134